TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma edoxaban concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Biomarkers of blood coagulation and fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decisional conflict uncertainty score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decisional conflict values clarity score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TNF‐α level (ng/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL‐6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MPO level (µg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in glucose concentrations (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in potassium concentrations (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean hemoglobin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean plasma ferritin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in ratio of optic cup area to optic disk area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: macular flow area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in at-risk alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of attending specialized treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-prandial glucose (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting glucose (FG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse events (thrombocytopenia, neutropenia, anemia)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of EyeSpy screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of EyeSpy screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence impact
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Role limitations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recovery of forced expiratory volume and forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to return of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Morphine usage post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QALY values
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: cost difference
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of AR symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: life appreciation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AML transformation
Endpoint domain: Adverse events/effects
Primary endpoint: Physiologic FDG activity in the small bowel and colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gain in bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of the osteotome technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant capacity (TEAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of thiobarbituric acid reactive substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic condition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: paroxysmal supraventricular tachycardia recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness in killing E. faecalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composite clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental Cost-Effectiveness Ratio (ICER) per patient/year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total tramadol consumption at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scores during 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall behavior scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL-C lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SF‐36 physical component scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 mental component scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in rescue albuterol use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in trough forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscle stiffness in the waist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mental task performance (reaction times)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of induction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Apnea incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea occurrence during dialysis sessions
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of birth of a small for gestational age infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Chemerin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progranulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean nighttime sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: mean wake time after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Occurrence of major adverse cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Development of Post-ERCP Pancreatitis (PEP)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of CNt
Endpoint domain: Adverse events/effects
Primary endpoint: Divided attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall mortality rate at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Forearm blood flow augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical domain score of the Oxford ankle foot questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative incidence of DGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nosocomial infections
Endpoint domain: Adverse events/effects
Primary endpoint: lumbar spine areal BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertebral trabecular volumetric BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal propeptide of type I collagen (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious contamination or urinary infection
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mass in distal radius or tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24-h ultrafiltration volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DCl/1.73 m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DCl/1.73 m2/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SjvO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AjvDO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Owner's perception of dog's itching level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma responses of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C‐peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: insulin secretory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Major adverse cardiovascular events (MACE) at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pearl index
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of pregnancy for BMI >or=25 kg/m2
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of pregnancy for body weight >or=70 kg
Endpoint domain: Mortality/survival
Primary endpoint: Labor initiation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean bishop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bone density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in comedonal lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active treatment increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient experience scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mental quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NobelGuide intervention score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission due to heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Effective rate of atrophy, intestinal metaplasia, dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cases of depressive disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to correct mandibular crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and frequency of GI reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity and frequency of cutaneous symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient's clinical condition perception (VAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Restoration of TLR2 and TLR9 responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expansion of FoxP3 1 regulatory T cells (Tregs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of asthma/reactive airway disease
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in efficacy parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health related quality of life impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: contrast volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for additional projections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy and safety of pertuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean subjective xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean objective xerostomia grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS Symptoms subscores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KOOS Activities of Daily Living (ADL) subscores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS Quality of Life (QoL) subscores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mortality prior to discharge home at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Attainment of lipid target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentrations of 6-keto-prostacyclin F(1α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t(1/2)) of 6-keto-prostacyclin F(1α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality due to GVHD complications
Endpoint domain: Mortality/survival
Primary endpoint: Serum ALT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Composite outcome of lip ulcers, facial skin tears, or endotracheal tube dislodgement
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of children with hypercalcemia and hypercalciuria at 7-10th day
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in symptoms of ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exclusive breastfeeding at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: formula use at 1 week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Restoration of hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Variceal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events (fever)
Endpoint domain: Adverse events/effects
Primary endpoint: Iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstrings area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Young Mania Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extrapyramidal Symptom Rating Scale total scores
Endpoint domain: Adverse events/effects
Primary endpoint: trait self-control score increase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concordance of functional dyspepsia symptom ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lowering of CSF levels of specific inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lowering of CSF levels of sAPPα, sAPPβ, t‐τ, p‐τ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trend to lower CSF Aβ(42)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: TEG maximum amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of confusion
Endpoint domain: Adverse events/effects
Primary endpoint: urinary complications (incontinence or retention)
Endpoint domain: Adverse events/effects
Primary endpoint: bowel complications (incontinence or constipation)
Endpoint domain: Adverse events/effects
Primary endpoint: patient and carer satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence rates of ICH associated with use of antithrombotic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PBMC proliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-gamma production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean AOC of ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidences of CIN
Endpoint domain: Adverse events/effects
Primary endpoint: Abstinence for illicit stimulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Total arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial to alveolar oxygen tension ratio (aAPO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Preventive care for urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Median survival times
Endpoint domain: Mortality/survival
Primary endpoint: 1-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: time of fixing operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: clearing of psoriatic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: erythema reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: scaling reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean visual acuity (VA) at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Persistent heroin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney graft loss
Endpoint domain: Mortality/survival
Primary endpoint: allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Bowel and urinary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects with more than 77% correct compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower esophageal sphincter (LES) tonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroesophageal reflux (DeMeester score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal Quality of Life Index (GIQLI) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall 2-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Grade 1 to 3 peripheral neuropathy cases
Endpoint domain: Adverse events/effects
Primary endpoint: Facial activity indicative of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in throat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in difficulty swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in throat swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first handgrip relaxation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure increase during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual cavity healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response at day 21-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical success rates on day 10-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes